Back to top
more

Cabot (CBT)

(Delayed Data from NYSE)

$72.00 USD

72.00
734,837

-0.18 (-0.25%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $72.10 +0.10 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 5% (233 out of 246)

Industry: Chemical - Diversified

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Hawkins (HWKN) Up 51% in 6 Months: What's Driving the Stock?

by Zacks Equity Research

Hawkins (HWKN) benefits from the robust Water Treatment segment, strategic acquisitions and a prudent pricing strategy.

Zacks Equity Research

CBT or AIQUY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CBT vs. AIQUY: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Cabot (CBT) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Why Cabot (CBT) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Cabot (CBT) Up 6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Cabot (CBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Cabot (CBT) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Zacks Equity Research

Why Cabot (CBT) is a Top Dividend Stock for Your Portfolio

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cabot (CBT) have what it takes? Let's find out.

Zacks Equity Research

Here's Why Cabot (CBT) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Cabot (CBT) Could Be a Great Choice

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cabot (CBT) have what it takes? Let's find out.

Zacks Equity Research

Should Value Investors Buy Cabot (CBT) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Cabot (CBT) Unveils REPLASBLAK Masterbatch Product Family

by Zacks Equity Research

Cabot's (CBT) newly released EVOLVE Sustainable Solutions technology platform is intended to create products with sustainable content and dependable performance at an industrial scale.

Zacks Equity Research

Cabot's (CBT) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

The decline in sales of Cabot's (CBT) Reinforcement Materials unit is due to reduced sales in the Americas and EMEA in the fiscal fourth quarter.

Zacks Equity Research

Cabot (CBT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Cabot (CBT) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Chemours (CC) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Chemours (CC) delivered earnings and revenue surprises of -16.88% and 3.63%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CBT vs. AIQUY: Which Stock Is the Better Value Option?

by Zacks Equity Research

CBT vs. AIQUY: Which Stock Is the Better Value Option?

Zacks Equity Research

Stepan Co. (SCL) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Stepan Co. (SCL) delivered earnings and revenue surprises of -15.79% and 6.88%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cabot (CBT) Boosts Circularity & Traceability With ISCC PLUS

by Zacks Equity Research

Cabot's (CBT) ISCC PLUS certified facilities adhere to ISCC PLUS requirements by leveraging circular value chains and certified feedstocks in the product manufacturing process.

Zacks Equity Research

Why Is Cabot (CBT) Up 2.2% Since Last Earnings Report?

by Zacks Equity Research

Cabot (CBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Cabot (CBT) Joins US Energy Department's Better Plants Program

by Zacks Equity Research

Cabot (CBT) believes that this engagement with the DOE will help the company boost its energy efficiency performance.

Zacks Equity Research

Cabot (CBT) Q3 Earnings & Revenues Miss Estimates, Fall Y/Y

by Zacks Equity Research

Cabot (CBT) lags third-quarter earnings and revenue estimates due to low volumes in its segments.

Zacks Equity Research

Compared to Estimates, Cabot (CBT) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Cabot (CBT) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Koppers (KOP) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Koppers (KOP) delivered earnings and revenue surprises of 16.67% and 8.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kronos Worldwide (KRO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kronos Worldwide (KRO) delivered earnings and revenue surprises of -170% and 16.02%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cabot (CBT) Announces Updates on Current Demand Scenario

by Zacks Equity Research

Cabot (CBT) expects EBIT in the Performance Chemical segment to be slightly higher in the fiscal third quarter than in the second quarter.

Zacks Equity Research

Why Is Cabot (CBT) Up 8.2% Since Last Earnings Report?

by Zacks Equity Research

Cabot (CBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.